Marina Biotech buys DyrctAxess technology to bolster Prestalia sales
Marina Biotech announced that it has acquired DyrctAxess Technology Platform from Symplmed Pharmaceuticals. DyrctAxess offers enhanced efficiency, control and information to empower patients, physicians and manufacturers to help achieve optimal care. The secure, web-based, HIPAA-compliant platform provides:The acquisition of DyrctAxes follows the recent acquisition of Prestalia and continues Marina's process of building a commercial organization which can support multiple products. Erik Emerson, Chief Commercial Officer of Marina Biotech, stated, "We will be building our sales and marketing capabilities around DyrctAxess with an eye toward building a commercial organization focused on efficiency, meeting patient needs and enhancing our patients' experience." Mr. Emerson continued, 'We look forward to leveraging this platform for products developed organically and those we pursue through licensing efforts."